…
Cannabis Bioscience International Holdings, Inc. engages in the provision of educational systems that focuses on medical cannabis in the United States and Latin America, and internationally. The company offers educational services, such as continuing medical education courses for physicians; continuing legal education courses for attorneys; certification courses for physicians; certification for industry workers; general education seminars; and on-site training, as well as consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University. It is also involved in clinical trials and medical research services through its Alpha Research Institute; and sale of CBD products. The company was founded in 2003 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cannabis Bioscience International Holdings Inc. (CBIH) is an OTC Pink–listed microcap that, based on public disclosures, operates in the cannabis/hemp sector with a stated focus on developing and commercializing cannabinoid-based products and related technologies. Major long-term growth drivers may include expansion of legal cannabis and hemp markets, product development, and potential regulatory changes that could support broader market access, and the company may appeal to investors seeking early-stage exposure if execution and funding materialize.
Key risks include limited public disclosure and low liquidity typical of OTC Pink microcaps, execution and financing risk that could constrain operations, and substantial regulatory and market uncertainty inherent to the cannabis industry.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Income before tax | -0.55M | -0.65M | -1.07M | -0.89M | -0.16M |
| Net income | -0.55M | -0.65M | -1.03M | -0.89M | -0.16M |
| Selling general administrative | 0.42M | 0.65M | 1.15M | - | - |
| Selling and marketing expenses | - | - | 0.05M | - | - |
| Gross profit | 0.26M | 0.20M | 0.22M | 0.17M | 0.76M |
| Reconciled depreciation | 0.03M | -0.01M | 0.04M | - | - |
| Ebit | -0.37M | -0.49M | -0.94M | - | -0.11M |
| Ebitda | -0.34M | -0.50M | -0.91M | -0.83M | -0.11M |
| Depreciation and amortization | 0.03M | -0.01M | 0.04M | - | 0.00M |
| Operating income | -0.42M | -0.49M | -0.98M | -0.89M | -0.11M |
| Other operating expenses | 0.72M | 0.73M | 1.30M | 1.10M | 0.88M |
| Interest expense | 0.18M | 0.17M | 0.09M | 0.05M | 0.04M |
| Net interest income | -0.18M | -0.17M | -0.09M | - | - |
| Income tax expense | - | 0.00M | -0.04M | - | -0.00M |
| Total revenue | 0.30M | 0.25M | 0.32M | 0.21M | 0.76M |
| Total operating expenses | 0.68M | 0.69M | 1.21M | 1.06M | 0.87M |
| Cost of revenue | 0.04M | 0.05M | 0.09M | 0.05M | 0.00M |
| Total other income expense net | -0.13M | -0.17M | -0.09M | 0.00M | -0.04M |
| Net income from continuing ops | -0.55M | -0.65M | -1.03M | - | - |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Total assets | 0.03M | 0.06M | 0.04M | 0.11M | 0.15M |
| Other current assets | 0.00M | 0.00M | 0.00M | - | - |
| Total liab | 1.20M | 1.14M | 0.64M | 0.47M | 0.45M |
| Total stockholder equity | -1.16M | -1.08M | -0.59M | -0.36M | -0.30M |
| Other current liab | 0.67M | 0.50M | 0.21M | 0.02M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.00M | - | - |
| Retained earnings | -5.88M | -5.33M | -4.68M | -3.65M | -2.76M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 0.01M | 0.00M | 0.01M | 0.03M | 0.04M |
| Total current liabilities | 0.95M | 0.88M | 0.39M | 0.22M | 0.19M |
| Current deferred revenue | - | - | 0.03M | - | - |
| Net debt | 0.41M | 0.44M | 0.38M | 0.35M | 0.38M |
| Short term debt | 0.17M | 0.18M | 0.14M | 0.14M | 0.16M |
| Short long term debt | 0.17M | 0.16M | 0.14M | - | - |
| Short long term debt total | 0.42M | 0.44M | 0.39M | 0.39M | 0.42M |
| Other stockholder equity | 4.72M | 4.26M | 4.09M | 3.29M | 2.46M |
| Total current assets | 0.03M | 0.02M | 0.02M | 0.05M | 0.05M |
| Net receivables | 0.02M | 0.02M | 0.01M | 0.02M | 0.01M |
| Long term debt | 0.25M | 0.25M | 0.25M | - | - |
| Inventory | - | - | -0.00M | - | - |
| Accounts payable | 0.10M | 0.20M | 0.11M | 0.07M | 0.02M |
| Non currrent assets other | - | - | -0.00M | - | - |
| Non current assets total | 0.00M | 0.04M | 0.02M | 0.06M | 0.09M |
| Capital lease obligations | 0.00M | 0.03M | 0.00M | - | - |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Net borrowings | 0.10M | 0.40M | 0.07M | - | - |
| Total cash from financing activities | 0.34M | 0.47M | 0.89M | 0.85M | 0.42M |
| Net income | -0.55M | -0.65M | -1.03M | -0.89M | -0.16M |
| Change in cash | 0.01M | -0.01M | -0.02M | -0.01M | -0.09M |
| Begin period cash flow | 0.00M | 0.01M | 0.03M | 0.04M | 0.13M |
| End period cash flow | 0.01M | 0.00M | 0.01M | 0.03M | 0.04M |
| Total cash from operating activities | -0.33M | -0.48M | -0.91M | -0.86M | -0.51M |
| Issuance of capital stock | 0.24M | 0.07M | 0.80M | - | - |
| Depreciation | 0.03M | -0.01M | 0.04M | - | 0.00M |
| Change to account receivables | 0.00M | -0.01M | -0.00M | -0.00M | -0.01M |
| Sale purchase of stock | - | - | - | - | -0.00M |
| Other cashflows from financing activities | 0.34M | - | - | - | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.06M | 0.05M | 0.16M | 0.02M | -0.35M |
| Stock based compensation | - | 0.00M | 0.01M | - | - |
| Other non cash items | 0.25M | 0.14M | -0.08M | -0.03M | 0.09M |
| Free cash flow | -0.33M | -0.48M | -0.91M | -0.86M | -0.51M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CBIH Cannabis Bioscience International Holdings Inc. |
0.00 100.00% |
0.00 | - | - | 37.62 | 0.01 | 40.90 | 0.02 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Cannabis Bioscience International Holdings, Inc. engages in the provision of educational systems that focuses on medical cannabis in the United States and Latin America, and internationally. The company offers educational services, such as continuing medical education courses for physicians; continuing legal education courses for attorneys; certification courses for physicians; certification for industry workers; general education seminars; and on-site training, as well as consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University. It is also involved in clinical trials and medical research services through its Alpha Research Institute; and sale of CBD products. The company was founded in 2003 and is headquartered in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Dante Picazo | CEO, Chief Accounting Officer & Director | 1956 |
| Mr. John Jones | Treasurer & Director | 1965 |
| Dr. Jose A. Torres Torres | National Medical Director, Secretary & Director | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.